Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer

BACKGROUND: The BYLieve trial (NCT03056755) confirmed efficacy and safety of alpelisib with fulvestrant for hormone receptor–positive (HR+), human epidermal growth factor receptor‐2–negative (HER2−), PIK3CA‐mutated advanced breast cancer (ABC), after cyclin‐dependent kinase 4/6 inhibitor (CDK4/6i) w...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Oncologist
मुख्य लेखकों: Turner, Stuart, Chia, Stephen, Kanakamedala, Hemanth, Hsu, Wei‐Chun, Park, Jinhee, Chandiwana, David, Ridolfi, Antonia, Yu, Chu‐Ling, Zarate, Juan Pablo, Rugo, Hope S.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: John Wiley & Sons, Inc. 2021
विषय:
Breast Cancer
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC8265362/
https://ncbi.nlm.nih.gov/pubmed/33909934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13804
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन